コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 and F1 score of TMS in differentiating each neurodegenerative disorder.
2 iency of NPC1 underlies the progressive NPC1 neurodegenerative disorder.
3 on's disease (PD) is a complex, multi-system neurodegenerative disorder.
4 n in NME3 is linked to a fatal mitochondrial neurodegenerative disorder.
5 spheroids (HDLS), an adult-onset progressive neurodegenerative disorder.
6 livery of bioactive factors for treatment of neurodegenerative disorder.
7 1 scores (0.89-0.95) in differentiating each neurodegenerative disorder.
8 ew, targeted therapeutic strategies for this neurodegenerative disorder.
9 y impairment in mouse and cellular models of neurodegenerative disorders.
10 ute to pathogenesis of diabetes mellitus and neurodegenerative disorders.
11 an abnormal biological process implicated in neurodegenerative disorders.
12 gy of a wide range of neurodevelopmental and neurodegenerative disorders.
13 stress could link to the pathophysiology of neurodegenerative disorders.
14 ifying method of therapeutic intervention in neurodegenerative disorders.
15 ctors of risk for major mental illnesses and neurodegenerative disorders.
16 romising approach for treatment of inherited neurodegenerative disorders.
17 ion and transcription, leading to cancer and neurodegenerative disorders.
18 g uniquely modified tau species in different neurodegenerative disorders.
19 p, miR-204-5p) are linked to psychiatric and neurodegenerative disorders.
20 orts to combat Alzheimer's disease and other neurodegenerative disorders.
21 ence clinical criteria, to predict different neurodegenerative disorders.
22 croglial cells, exerts beneficial effects in neurodegenerative disorders.
23 tivity of clinical trials at early stages of neurodegenerative disorders.
24 lammation can affect the progression of some neurodegenerative disorders.
25 etween HD symptoms and risk scores for other neurodegenerative disorders.
26 mitophagy correlate with aging phenomena and neurodegenerative disorders.
27 hibitors a viable approach to treat multiple neurodegenerative disorders.
28 nce of Alzheimer's disease, as well as other neurodegenerative disorders.
29 n developing immune modulatory therapies for neurodegenerative disorders.
30 for the interpretation of TSPO PET in other neurodegenerative disorders.
31 in the cerebrospinal fluid causing childhood neurodegenerative disorders.
32 ceroid lipofuscinoses, a group of pediatric neurodegenerative disorders.
33 he development of cancer and several related neurodegenerative disorders.
34 al role in human diseases such as cancer and neurodegenerative disorders.
35 ration in Parkinson's disease (PD) and other neurodegenerative disorders.
36 unction of the endosomal-lysosomal system in neurodegenerative disorders.
37 e to various features of the entire class of neurodegenerative disorders.
38 etal and metal-oxide nanoparticles and major neurodegenerative disorders.
39 implicated in the pathogenesis of a range of neurodegenerative disorders.
40 ized throughout AFG3L2 are linked to diverse neurodegenerative disorders.
41 e for designing new treatments toward myriad neurodegenerative disorders.
42 may also bear possible implications in some neurodegenerative disorders.
43 may offer a new approach to the treatment of neurodegenerative disorders.
44 eature of Alzheimer's disease (AD) and other neurodegenerative disorders.
45 or cardiovascular disease, stroke, and other neurodegenerative disorders.
46 locomotor impairment, a common phenotype of neurodegenerative disorders.
47 hies that are presumptive "triggers" of many neurodegenerative disorders.
48 hology of Alzheimer's disease (AD) and other neurodegenerative disorders.
49 I is recognized as risk factor for late-life neurodegenerative disorders.
50 pathophysiology of several neurological and neurodegenerative disorders.
51 pment of therapeutics for RBD and associated neurodegenerative disorders.
52 an increasing number of genetically diverse neurodegenerative disorders.
53 is reported as underlying the progression of neurodegenerative disorders.
54 tly emerged as an attractive drug target for neurodegenerative disorders.
55 symptom in a number of neuropsychiatric and neurodegenerative disorders.
56 gical and therapeutic implications for other neurodegenerative disorders.
57 on and transport defects have been linked to neurodegenerative disorders.
58 ant therapeutic target for managing multiple neurodegenerative disorders.
59 maintain brain homeostasis and contribute to neurodegenerative disorders.
60 n rodent models of stroke, brain injury, and neurodegenerative disorders.
61 of which participate in the pathogenesis of neurodegenerative disorders.
62 r both can cause, or alter risk for, various neurodegenerative disorders.
63 holic fatty liver disease and autoimmune and neurodegenerative disorders.
64 en the genetic architecture of DLB and other neurodegenerative disorders.
65 ogical diseases, including brain cancers and neurodegenerative disorders.
66 and the pathogenic process in AD and related neurodegenerative disorders.
67 rately distinguishes AD dementia from non-AD neurodegenerative disorders.
68 aging and the development of both cancer and neurodegenerative disorders.
69 feature of Alzheimer disease (AD) and other neurodegenerative disorders.
70 and BioFINDER-2 included patients with other neurodegenerative disorders.
71 rontotemporal dementia (FTD) are overlapping neurodegenerative disorders.
72 lar mechanisms of CNS protein aggregation in neurodegenerative disorders.
73 towards tackling HD as well as other similar neurodegenerative disorders.
74 therapeutic targets and their modulation in neurodegenerative disorders.
75 contributor to many human diseases including neurodegenerative disorders.
76 n in iron deficient children and adults with neurodegenerative disorders.
77 ic target for age-related diseases including neurodegenerative disorders.
78 ets for therapies for neurodevelopmental and neurodegenerative disorders.
79 teger numbers of trinucleotides that lead to neurodegenerative disorders.
80 with accelerated aging and enhanced risk for neurodegenerative disorders.
81 risk of brain diseases, including cancer and neurodegenerative disorders.
82 ovide new avenues to combat aging-associated neurodegenerative disorders.
83 modifying gene therapy to treat HD and other neurodegenerative disorders.
84 henols in the context of these metabolic and neurodegenerative disorders.
85 Axon degeneration is a hallmark of many neurodegenerative disorders.
89 son's Disease (PD) is the second most common neurodegenerative disorder, affecting more than 1% of th
91 normal brain development and function and in neurodegenerative disorders align with complement-mediat
92 C9orf72 gene is the most common cause of the neurodegenerative disorder amyotrophic lateral sclerosis
93 g protein) are a hallmark of the overlapping neurodegenerative disorders amyotrophic lateral sclerosi
94 son's disease (PD) is the second most common neurodegenerative disorder and a central role for alpha-
95 sease (AD) is a progressive and debilitating neurodegenerative disorder and one of the leading causes
97 Spinal Muscular Atrophy (SMA) is a monogenic neurodegenerative disorder and the leading genetic cause
101 athophysiological insights across a range of neurodegenerative disorders and enhanced our understandi
102 therapeutics in the treatment of cancer and neurodegenerative disorders and for tissue regeneration.
103 nderlies pathogenesis of numerous congenital neurodegenerative disorders and is an early and progress
104 and life-threatening human diseases, such as neurodegenerative disorders and many heart diseases.
105 -wide association studies of psychiatric and neurodegenerative disorders and of intelligence and 2) t
106 Lysosome pH (pHlys) is often increased in neurodegenerative disorders and predicted to be decrease
107 ome human diseases such as developmental and neurodegenerative disorders and some cancers linked to g
108 p between altered mind wandering capacity in neurodegenerative disorders and structural and functiona
110 Alzheimer's disease (AD) is the most common neurodegenerative disorder, and several studies using th
111 son's disease (PD) is one of the most common neurodegenerative disorders, and both genetic and histop
114 differentiate Alzheimer's disease from other neurodegenerative disorders, and identify Alzheimer's di
115 with motor and cognitive decline in multiple neurodegenerative disorders, and the cellular redistribu
116 ve fission has been associated with multiple neurodegenerative disorders, and we recently reported th
118 TATEMENT Current strategies for treatment of neurodegenerative disorders are focused on the repair of
120 CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structur
121 hondrial bioenergetics, as observed in other neurodegenerative disorders, are significantly altered i
122 ic potential for many neurodevelopmental and neurodegenerative disorders as a consequence of its modu
123 mely, neurodevelopmental, neurometabolic and neurodegenerative disorders, as well as disorders with c
124 ntia (FTD) is a pathologically heterogeneous neurodegenerative disorder associated usually with tau o
126 sociated Tremor/Ataxia Syndrome (FXTAS) is a neurodegenerative disorder associated with the FMR1 prem
127 t the pathogenesis of inherited and sporadic neurodegenerative disorders associated with pathological
128 tory medicines for lung diseases, hepatitis, neurodegenerative disorders, autoimmune disorders and in
129 task to probe mind wandering capacity in two neurodegenerative disorders: behavioral variant frontote
130 h Huntington's disease is a late-manifesting neurodegenerative disorder, both mouse studies and neuro
131 ther neuronal protein critically involved in neurodegenerative disorders but, in contrast to alpha-sy
132 athophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalabi
133 eath is a shared feature of normal aging and neurodegenerative disorders, but the intracellular mecha
136 Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a CAG repeat expans
137 se (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expans
138 ton's disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide
139 Huntington's disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG rep
141 (HD) is a fatal inherited autosomal dominant neurodegenerative disorder caused by an expansion in the
143 Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder caused by mutations in NPC1 a
144 Huntington's disease (HD) is an inherited neurodegenerative disorder caused by the expansion of th
145 Parkinson's disease (PD) is a debilitating neurodegenerative disorder caused by the loss of midbrai
146 yotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder caused by the loss of motor n
148 ontrol in neurons contributes to age-related neurodegenerative disorders caused by misfolded proteins
152 amilial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combinatio
155 herapies against Alzheimer's disease (AD), a neurodegenerative disorder characterized by high amounts
157 disease (LD) is a genetic and fatal form of neurodegenerative disorder characterized by myoclonic ep
159 Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by the presence
160 ington disease (HD) is an autosomal dominant neurodegenerative disorder characterized by variable mot
161 a Drosophila model of tauopathy, a class of neurodegenerative disorders characterized by the accumul
162 ifactorial malady and the second most common neurodegenerative disorder, characterized by loss of dop
163 e known to drive human maladies, such as the neurodegenerative disorder Charcot-Marie-Tooth disease a
165 In particular, vps13A mutants result in the neurodegenerative disorder Chorea-Acanthocytosis (ChAc).
169 tives were more frequent among patients with neurodegenerative disorders compared with patients with
170 a ubiquitous feature associated with several neurodegenerative disorders, especially Alzheimer's dise
171 e the role of SUMOylation in the etiology of neurodegenerative disorders, focusing on Parkinson's dis
174 iciency in FXN leads to the loss-of-function neurodegenerative disorder Friedreich's ataxia (FRDA).
175 phic lateral sclerosis (ALS) and the related neurodegenerative disorder frontotemporal dementia, is t
176 in involved in Alzheimer's disease and other neurodegenerative disorders, has a propensity to undergo
179 ts to develop neuroprotective treatments for neurodegenerative disorders have not yet been clinically
180 of chronic traumatic encephalopathy (CTE), a neurodegenerative disorder histopathologically character
181 important contributor to pathogenesis of the neurodegenerative disorder Huntington's disease (HD).
184 tion in the basal ganglia is associated with neurodegenerative disorders in aging and cognitive defic
186 he frontotemporal dementia (FTD) spectrum of neurodegenerative disorders includes a heterogeneous gro
187 as been implicated in the aetiology of other neurodegenerative disorders including Alzheimer's diseas
188 f different microRNAs (miRNAs) is altered in neurodegenerative disorders including tauopathies, a gro
189 f 43 kDa (TDP-43) is associated with several neurodegenerative disorders, including ALS, frontotempor
190 ters in the differential diagnosis of common neurodegenerative disorders, including Alzheimer disease
191 ted in aging and the pathogenesis of several neurodegenerative disorders, including Alzheimer's and P
192 ing and potentially treating a wide range of neurodegenerative disorders, including Alzheimer's and P
193 ature contributing to obesity, diabetes, and neurodegenerative disorders, including Alzheimer's disea
194 correlate with cognitive decline in several neurodegenerative disorders, including Alzheimer's disea
196 Neuronal activity patterns are disrupted in neurodegenerative disorders, including Alzheimer's disea
197 ranules have been implicated in a variety of neurodegenerative disorders, including amyotrophic later
198 .21-98.24% across cohorts), as well as other neurodegenerative disorders, including frontotemporal de
199 t is genetically implicated in a spectrum of neurodegenerative disorders, including Kufor-Rakeb syndr
200 cles has been recently implicated in various neurodegenerative disorders, including Parkinson's disea
201 A2 (PARK9) are associated with a spectrum of neurodegenerative disorders, including Parkinson's disea
202 rotein are common disease mechanisms in many neurodegenerative disorders, including Parkinson's disea
203 vely targeting CB2 hold promise for treating neurodegenerative disorders, inflammation, and pain whil
204 defects could be initiators of these common neurodegenerative disorders, instead of being consequenc
205 Parkinson's disease (PD) is a progressive neurodegenerative disorder involving dopaminergic neuron
206 ifiers of dosage-sensitive genes involved in neurodegenerative disorders is imperative to discover no
207 rks of Alzheimer's disease and several other neurodegenerative disorders is the aggregation of tau pr
208 's disease (AD), the most common age-related neurodegenerative disorder, is currently conceptualized
209 ide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy f
210 se pathological aggregation is implicated in neurodegenerative disorders, is not well understood.
211 merged as a robust fluid biomarker for fatal neurodegenerative disorders like amyotrophic lateral scl
212 a recognized impediment to the treatment of neurodegenerative disorders like Parkinson's disease (PD
213 ys but shared impacts on pathways related to neurodegenerative disorders, like Alzheimer's, which cou
214 ating enzyme and the affected protein in the neurodegenerative disorder Machado-Joseph disease (MJD).
215 ease (AD) is an irreversible and progressive neurodegenerative disorder manifested by memory loss and
217 lack of biomarkers for an early diagnosis of neurodegenerative disorders (NDs) has hampered the devel
218 in patients with stroke, status epilepticus, neurodegenerative disorders, neurotrauma, and neoplasms,
219 condition has similar heritability to other neurodegenerative disorders, no other genetic risk loci
221 Parkinson's disease (PD) is the most common neurodegenerative disorder of midlife, while Alzheimer's
224 cts of therapeutic strategies for countering neurodegenerative disorders of ageing by improving, pres
226 uscinosis (NCL) is one of the most prevalent neurodegenerative disorders of early life, Parkinson's d
227 (PD) and Alzheimer's disease (AD) are common neurodegenerative disorders of the elderly and, therefor
228 encephalopathies comprise a diverse group of neurodegenerative disorders of white matter with a wide
229 d the pathologies of CTE with those of other neurodegenerative disorders or of age-matched controls.
230 ebrospinal fluid features of the most common neurodegenerative disorders outside the AD continuum and
231 dysfunction has long been implicated in the neurodegenerative disorder Parkinson's disease (PD); how
233 hat it plays in the development of two major neurodegenerative disorders, Parkinson's disease and Alz
234 peared to be involved in the pathogenesis of neurodegenerative disorders, particularly Alzheimer's di
236 nervous system is associated with a group of neurodegenerative disorders referred to as the synuclein
237 ent form of Batten disease, is a progressive neurodegenerative disorder resulting from mutations in t
238 araplegias refer to a heterogeneous group of neurodegenerative disorders resulting from degeneration
239 Alzheimer's disease (AD) is the most common neurodegenerative disorder, resulting in the progressive
240 gestation and in excitatory neurons, whereas neurodegenerative-disorder risk genes showed increasing
241 genesis, and is also mutated in a hereditary neurodegenerative disorder, spinocerebellar ataxia type
242 D, suggest that the key proteins involved in neurodegenerative disorders such as alpha-synuclein and
245 identified as a contributor to aging-related neurodegenerative disorders such as Alzheimer's disease.
247 ating fibrils that are closely tied to fatal neurodegenerative disorders such as amyotrophic lateral
248 cluding neurodevelopmental, psychiatric, and neurodegenerative disorders such as autism spectrum diso
249 polyneuropathies associated with progressive neurodegenerative disorders such as mitochondrial ataxia
251 (BD), and schizophrenia (SZ), as well as in neurodegenerative disorders, such as Alzheimer disease (
252 deficiencies have been observed in numerous neurodegenerative disorders, such as Alzheimer's and Par
253 in neuropsychiatric, neurodevelopmental, and neurodegenerative disorders, suggesting that uncoupling
255 taxia syndrome (FXTAS) is a late adult-onset neurodegenerative disorder that affects movement and cog
256 or/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder that affects premutation carr
257 Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder that is associated with repet
258 Huntington's disease (HD) is a monogenetic neurodegenerative disorder that is caused by the expansi
259 ateral sclerosis (ALS) is a late-onset fatal neurodegenerative disorder that is predicted to increase
261 Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the sixth leading cau
263 Alzheimer's disease (AD) is a progressive neurodegenerative disorder that presently affects an est
264 Prion diseases are a group of incurable neurodegenerative disorders that affect humans and anima
265 Prion diseases are a unique, infectious, neurodegenerative disorders that can affect animals and
266 ht chain, are likely to be relevant to other neurodegenerative disorders that involve similar patholo
267 (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders that overlap in their clinic
269 diseases are rare and usually rapidly fatal neurodegenerative disorders, the most common being spora
270 of abuse and drugs for neuropsychiatric and neurodegenerative disorders, their mechanism of action a
271 developing disease-modifying treatments for neurodegenerative disorders there is a need to develop n
272 hat, although the HD mutation causes a fatal neurodegenerative disorder, there may be premorbid benef
274 several maladies, such as obesity, pain, and neurodegenerative disorders, there is interest in develo
275 MAGMA to five psychiatric disorders and four neurodegenerative disorders to interrogate biological pa
277 .g. developmental pruning, toxic insult from neurodegenerative disorder), Wallerian degeneration asso
278 under clinical development for treatment of neurodegenerative disorders, was evaluated in nonhuman p
280 Parkinson's disease (PD) is a progressive neurodegenerative disorder whose cardinal motor symptoms
282 S13A lead to chorea-acanthocytosis (ChAc), a neurodegenerative disorder with accelerated suicidal neu
283 pathogenesis of Huntington's disease (HD), a neurodegenerative disorder with frequent midlife onset,
284 Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with important vascular and h
285 edreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment.
287 Dementia with Lewy Bodies (DLB) is a common neurodegenerative disorder with poor prognosis and mainl
289 syndrome (WS) is a heterogeneous multisystem neurodegenerative disorder with two allelic variations i
290 noses (NCLs) are a group of fatal, monogenic neurodegenerative disorders with an early onset in infan
292 Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases
293 otrophic Lateral Sclerosis (ALS), is a fatal neurodegenerative disorder, with TDP-43 inclusions as a
294 e discuss the role of axonal degeneration in neurodegenerative disorders, with a focus on SARM1 and t
295 h highlighting the role of EVs in health and neurodegenerative disorders, with a specific focus on ne
297 s disease (AD) is the most prevalent form of neurodegenerative disorders, yet no major breakthroughs
298 f vertebrate synapses and are compromised in neurodegenerative disorders, yet the fundamental mechani
299 ubunits, as well as CLP1, are known to cause neurodegenerative disorders, yet the mechanisms underlyi
300 ociated protein tau (MAPT) underlie multiple neurodegenerative disorders, yet the pathophysiological